查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963981

子宮頸發育不良診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、最終用戶、地區和競爭對手分類，2021-2031年

Cervical Dysplasia Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球子宮頸發育不良診斷市場預計將從 2025 年的 8.505 億美元成長到 2031 年的 11.4041 億美元，複合年成長率達到 5.01%。

這個市場領域涵蓋用於識別子宮頸癌前細胞變化（例如子宮頸抹片檢查、HPV DNA檢測和陰道鏡檢查）的醫療檢測和治療設備，這些設備旨在預防子宮頸癌的惡性轉化。該市場的成長主要受全球人類乳突病毒感染疾病的日益蔓延以及各國嚴格篩檢通訊協定的推動。此外，公眾意識的提高和政府宣傳活動的加強也進一步強化了這些關鍵促進因素，強調了早期檢測在降低死亡率方面的重要性，從而確保了對精準篩檢方法的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 8.505億美元
市場規模：2031年 1,140,​​410,000 美元
複合年成長率：2026-2031年 5.01%
成長最快的細分市場 診斷測試
最大的市場 北美洲

然而，先進分子診斷技術的高成本是市場擴張的一大障礙。這限制了醫療基礎設施不足的發展中地區的應用。這種經濟差距導致疾病有效管理水準的差異，並阻礙了最需要此類技術的資源匱乏地區的市場滲透。根據美國癌症協會估計，到2025年，美國預計將新增13,360例浸潤性子宮頸癌病例，凸顯了持續開發便捷可靠的診斷工具以預防疾病進展的必要性。

市場促進因素

從傳統細胞學到先進分子診斷技術（尤其是HPV DNA檢測和自採集技術）的轉變是推動市場發展的主要因素。這些技術進步透過提供侵入性較小的選擇來提高篩檢依從性，並擴大了服務不足人口的診斷覆蓋範圍。例如，在2024年5月的新聞稿中，貝克頓·迪金森公司宣布，美國食品藥物管理局（FDA）已核准其自採集檢體HPV檢測方法在醫療機構中使用。此類監管進展正在加速高精度檢測工具作為傳統巴氏抹片檢查替代方案的普及，並迫使實驗室升級其診斷基礎設施以維持臨床有效性。

同時，政府資助的篩檢計畫的嚴格實施以及國際財政支持的承諾正顯著推動市場擴張。全球正致力於透過補貼篩檢費用和對中低收入地區基礎設施進行大規模投資來減輕疾病負擔。根據世界衛生組織（世衛組織）2024年3月發布的新聞稿，各國政府和捐款者承諾提供約6億美元，以擴大全球疫苗接種、篩檢和治療工具的覆蓋範圍。這筆資金將直接用於採購實現根除目標所需的診斷試劑盒和陰道鏡設備，鑑於世衛組織已將子宮頸癌列為2024年全球女性第四大常見癌症，這筆資金至關重要。

市場挑戰

先進分子診斷技術的高成本是限制全球子宮頸發育不良診斷市場成長的主要障礙。在醫療基礎設施薄弱的發展中地區，實施和維護自動化篩檢平台的財務負擔往往超出可用預算。這種經濟壓力迫使醫療機構依賴成本較低的方法或大幅縮減篩檢範圍。因此，製造商難以在這些資源匱乏的地區建立業務基礎，導致整體檢測利用率有限。

這種價格障礙造成了市場滲透率的嚴重失衡，導致高風險族群儘管迫切需要早期篩檢干預，卻無法獲得足夠的醫療服務。根據世界衛生組織（世衛組織）2024年的數據，全球整體約94%的子宮頸癌死亡病例發生在低收入和中等收入國家。這一數字清楚地表明，臨床負擔最重的地區由於經濟限制而無法獲得現代診斷解決方案。因此，無法調整產品價格以配合這些發展中經濟體的購買力，是潛在市場規模（TAM）的限制因素。

市場趨勢

將人工智慧 (AI) 整合到數位病理學和細胞學中，從根本上改變了檢查室的工作流程，提高了診斷準確性和操作效率。診斷中心擴大使用深度學習演算法來分析數位化切片影像，並以比人工顯微鏡更高的靈敏度識別癌前病變。這種技術變革實現了高風險樣本的自動優先排序，直接解決了高通量檢體環境中人為錯誤的風險。例如，Hologic 公司在 2024 年 2 月的新聞稿中報告稱，其獲得 FDA 批准的 Genius 數位篩檢系統與傳統顯微鏡相比，將高級別鱗狀上皮內病變的假陰性率降低了 28%，為篩檢準確性樹立了新的標竿。

同時，HPV陽性患者管理的關鍵趨勢是擴大採用p16/Ki-67雙染生物標記進行分診。這種免疫組織化學方法透過檢測兩種特定蛋白質的同時存在來識別性行為感染，與傳統的巴氏抹片細胞學檢查相比，其風險分層具有更高的特異性。透過準確區分短暫性行為感染和進行性惡性感染，該方法顯著最佳化了患者管理，並減少了不必要的後續觀察程序。根據羅氏診斷公司2024年3月發布的關於新臨床指南的新聞稿，IMPACT試驗的數據顯示，在10名HPV陽性女性中，有7名女性的子宮頸疾病檢測結果早於巴氏抹片細胞學檢查，這支持了其在臨床實踐中日益廣泛的應用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球子宮頸發育不良診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（診斷測試、診斷設備、其他）
    • 按最終使用者（醫院、診斷中心、研究和學術機構、門診手術中心等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美子宮頸發育不良診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲子宮頸發育不良診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區子宮頸發育不良診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲子宮頸發育不良診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲子宮頸發育不良診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球子宮頸發育不良診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • Becton Dickinson & Company
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • QIAGEN, LLC
  • Quest Diagnostics Incorporated
  • CooperSurgical, Inc.
  • Micromedic Technologies Ltd.
  • Karl Kaps GmbH & Co. KG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24590

The Global Cervical Dysplasia Diagnostic Market is projected to expand from USD 850.50 Million in 2025 to USD 1140.41 Million by 2031, achieving a CAGR of 5.01%. This market sector comprises medical assays and procedural instruments, such as Pap smears, HPV DNA testing, and colposcopy, designed to identify precancerous cellular changes on the cervix prior to malignancy. The growth of this market is largely driven by the rising global prevalence of Human Papillomavirus infections and the strict application of national screening protocols. These primary drivers are further supported by increased public awareness campaigns and government initiatives that highlight the vital importance of early detection in lowering mortality rates, thereby ensuring a continuous demand for precise screening methods.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 850.50 Million
Market Size 2031USD 1140.41 Million
CAGR 2026-20315.01%
Fastest Growing SegmentDiagnostic Tests
Largest MarketNorth America

However, a substantial obstacle hindering broader market expansion is the high cost linked to advanced molecular diagnostic technologies, which limits their adoption in developing regions with insufficient healthcare infrastructure. This economic disparity results in a gap in effective disease management, restricting the market's reach in low-resource settings where it is frequently most needed. According to the American Cancer Society, an estimated 13,360 new cases of invasive cervical cancer will be diagnosed in the United States in 2025, emphasizing the enduring need for accessible and dependable diagnostic interventions to prevent disease progression.

Market Driver

The transition from traditional cytology to advanced molecular diagnostics, specifically HPV DNA testing and self-collection techniques, acts as a primary market accelerator. These technological advancements improve screening adherence by providing less invasive options, thus extending diagnostic access to under-screened populations. For instance, Becton, Dickinson and Company announced in a May 2024 press release that the US Food and Drug Administration approved their HPV assay for use with self-collected vaginal specimens in a healthcare setting. Such regulatory achievements encourage the adoption of high-precision tools over conventional Pap smears, compelling laboratories to upgrade their diagnostic infrastructure to maintain clinical efficacy.

Simultaneously, the rigorous enforcement of government-funded screening programs and international financial pledges significantly drives market expansion. Global initiatives focus on reducing disease burden through major investments that subsidize screening costs and improve infrastructure in low-to-middle-income regions. According to a March 2024 World Health Organization news release, governments and donors pledged nearly $600 million to expand global access to vaccination, screening, and treatment tools. This funding directly supports the procurement of diagnostic kits and colposcopy devices needed to meet elimination targets, which is essential given that the World Health Organization identified cervical cancer as the fourth most common cancer in women globally in 2024.

Market Challenge

The high costs associated with advanced molecular diagnostic technologies present a significant restraint on the growth of the global cervical dysplasia diagnostic market. In developing regions with limited healthcare infrastructure, the financial burden of acquiring and maintaining automated screening platforms frequently exceeds available budgets. This economic pressure forces healthcare facilities to rely on less expensive methods or to significantly restrict screening coverage. Consequently, manufacturers struggle to establish a presence in these low-resource areas, which limits the overall volume of test utilization.

This pricing barrier creates a severe imbalance in market penetration, leaving high-risk populations underserved despite the clear need for early detection interventions. Data from the World Health Organization in 2024 indicates that approximately 94% of all cervical cancer deaths worldwide occurred in low- and middle-income countries. This figure demonstrates that regions with the highest clinical burden are currently unable to access modern diagnostic solutions due to economic constraints. Therefore, the inability to align product pricing with the purchasing power of these developing economies restricts the total addressable market.

Market Trends

The integration of Artificial Intelligence into digital pathology and cytology is fundamentally transforming laboratory workflows by improving diagnostic precision and operational efficiency. Diagnostic centers are increasingly utilizing deep-learning algorithms to analyze digitized slide images, identifying precancerous lesions with higher sensitivity than manual microscopic reviews. This technological shift automates the prioritization of high-risk samples, directly addressing human error risks in high-volume screening environments. For example, Hologic Inc. reported in a February 2024 press release that their FDA-cleared Genius Digital Diagnostics System achieved a 28% reduction in false-negatives for high-grade squamous intraepithelial lesions compared to traditional microscopic review, setting a new standard for screening accuracy.

Concurrently, the adoption of p16/Ki-67 dual-staining biomarkers for triage is emerging as a critical trend for managing patients with HPV-positive results. This immunocytochemical method detects the simultaneous presence of two specific proteins to identify transforming infections, offering superior specificity over conventional Pap cytology for risk stratification. By accurately distinguishing between transient infections and those progressing to malignancy, this approach significantly optimizes patient management and reduces unnecessary follow-up procedures. According to a March 2024 Roche Diagnostics press release regarding new clinical guidelines, data from the IMPACT trial showed that this dual-stain technology detected cervical disease earlier than Pap cytology in seven out of ten HPV-positive women, validating its growing role in clinical practice.

Key Market Players

  • Abbott Laboratories Inc.
  • Becton Dickinson & Company
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • QIAGEN, LLC
  • Quest Diagnostics Incorporated
  • CooperSurgical, Inc.
  • Micromedic Technologies Ltd.
  • Karl Kaps GmbH & Co. KG

Report Scope

In this report, the Global Cervical Dysplasia Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cervical Dysplasia Diagnostic Market, By Product Type

  • Diagnostic Tests
  • Diagnostic Devices
  • Others

Cervical Dysplasia Diagnostic Market, By End User

  • Hospitals
  • Diagnostic Centers
  • Research & Academic Institutes
  • Ambulatory Surgical Centers
  • Others

Cervical Dysplasia Diagnostic Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cervical Dysplasia Diagnostic Market.

Available Customizations:

Global Cervical Dysplasia Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cervical Dysplasia Diagnostic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Diagnostic Tests, Diagnostic Devices, Others)
    • 5.2.2. By End User (Hospitals, Diagnostic Centers, Research & Academic Institutes, Ambulatory Surgical Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cervical Dysplasia Diagnostic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cervical Dysplasia Diagnostic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Cervical Dysplasia Diagnostic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Cervical Dysplasia Diagnostic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End User

7. Europe Cervical Dysplasia Diagnostic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cervical Dysplasia Diagnostic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Cervical Dysplasia Diagnostic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Cervical Dysplasia Diagnostic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Cervical Dysplasia Diagnostic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Cervical Dysplasia Diagnostic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Cervical Dysplasia Diagnostic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cervical Dysplasia Diagnostic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Cervical Dysplasia Diagnostic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Cervical Dysplasia Diagnostic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Cervical Dysplasia Diagnostic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Cervical Dysplasia Diagnostic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Cervical Dysplasia Diagnostic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cervical Dysplasia Diagnostic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Cervical Dysplasia Diagnostic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Cervical Dysplasia Diagnostic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End User

10. South America Cervical Dysplasia Diagnostic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cervical Dysplasia Diagnostic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Cervical Dysplasia Diagnostic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Cervical Dysplasia Diagnostic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cervical Dysplasia Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Becton Dickinson & Company
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Hologic Inc.
  • 15.5. QIAGEN, LLC
  • 15.6. Quest Diagnostics Incorporated
  • 15.7. CooperSurgical, Inc.
  • 15.8. Micromedic Technologies Ltd.
  • 15.9. Karl Kaps GmbH & Co. KG

16. Strategic Recommendations

17. About Us & Disclaimer